NeuBase Therapeutics
(NASDAQ) NBSE
NeuBase Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$13.73M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
NBSE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout NeuBase Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
37
CEO
Dietrich A. Stephan, PhD
Website
www.neubasetherapeutics.comHeadquarters
Pittsburgh, PA 15219, US
NBSE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-89%
Return on Capital
-1%
Return on Assets
-1%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$1.26M
Operating Income
$33.32M
EBITDA
$32.92M
Operating Cash Flow
$29.01M
Capital Expenditure
$471.71K
Free Cash Flow
$29.48M
Cash & ST Invst.
$23.15M
Total Debt
$6.00M
NeuBase Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$250.00K
+25.4%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
37
N/A
Net Income
$1.82M
+76.1%
EBITDA
$1.57M
+78.5%
Quarterly Fundamentals
Net Cash
$7.24M
-57.8%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
+100.0%
Long Term Debt
$4.83M
-9.4%
Short Term Debt
$500.82K
-24.2%
Return on Assets
-1.05%
N/A
Return on Invested Capital
-1.17%
N/A
Free Cash Flow
$2.00M
+70.0%
Operating Cash Flow
$2.00M
+69.8%